Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022;12(8):2293-2296.
doi: 10.3233/JPD-229008.

This is NOT the End for Immunotherapy in Parkinson's Disease - A Perspective from Early Drug Development Scientists

Patrik Brundin  1 , Hanno Svoboda  1   2 , Azad Bonni  1 , Gennaro Pagano  1
Affiliations
Free article
Comment

This is NOT the End for Immunotherapy in Parkinson's Disease - A Perspective from Early Drug Development Scientists

Patrik Brundin et al. J Parkinsons Dis. 2022.
Free article
No abstract available

PubMed Disclaimer

Comment on

  • Trial of Prasinezumab in Early-Stage Parkinson's Disease.
    Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.

Substances

LinkOut - more resources